<DOC>
	<DOCNO>NCT01638936</DOCNO>
	<brief_summary>The purpose study test safety anti-tumor activity BT062 combination lenalidomide dexamethasone define best dos treat patient relapsed refractory multiple myeloma .</brief_summary>
	<brief_title>BT062 Combination With Lenalidomide Pomalidomide Dexamethasone Patients With Multiple Myeloma</brief_title>
	<detailed_description>BT062 antibody-drug conjugate design bind destroy Myeloma cell . The study drug give multiple dos standard Multiple Myeloma treatment , lenalidomide dexamethasone , test well treatment tolerate work together . This study dose escalation study purpose find high dose BT062 subject tolerate combination lenalidomide dexamethasone .</detailed_description>
	<mesh_term>Multiple Myeloma</mesh_term>
	<mesh_term>Neoplasms , Plasma Cell</mesh_term>
	<mesh_term>Dexamethasone acetate</mesh_term>
	<mesh_term>Dexamethasone</mesh_term>
	<mesh_term>Dexamethasone 21-phosphate</mesh_term>
	<mesh_term>Lenalidomide</mesh_term>
	<mesh_term>Pomalidomide</mesh_term>
	<mesh_term>BB 1101</mesh_term>
	<criteria>Inclusion Criteria Diagnosis active Multiple Myeloma accord International Myeloma Working Group ( IMWG ) diagnostic criterion Relapsed relapsed/refractory progressive Multiple Myeloma Subjects fail least one prior therapy ( BT062/Len/dex ) Subjects fail least two prior therapy ( BT062/Pom/dex ) Subjects age ≥18 year Life expectancy ≥12 week Eastern Cooperative Oncology Group ( ECOG ) performance status ( Zubrod ) ≤2 Normal organ bone marrow Signed write informed consent accordance federal , local , institutional guideline Subjects must agree follow Guidelines REVLIMID REMS Program POMALYST REMS Women child bear potential ( WCBP ) , must agree use 2 contraceptive method Chemotherapy radiotherapy within 3 week ( 6 week nitrosoureas mitomycin C ) prior day 1 recovered adverse event ( AEs ) due agent administer 3 week earlier Antineoplastic therapy biological agent within 2 week day 1 within 5 drug halflives ( t½ ) prior first dose , whichever time period longer Concomitant antineoplastic therapy include chemotherapy , radiotherapy , biological agent study Treatment another investigational drug study within 3 week day 1 within 5 drug halflive ( t½ ) prior first dose , whichever time period longer Treatment BT062 previous study Major surgery within 4 week day 1 ( include placement vascular access device tumor biopsy ) Malignancy within 3 year day 1 , trial indication multiple myeloma exclude treat nonmelanoma skin cancer , superficial bladder cancer , carcinoma insitu cervix prostate carcinoma ≤ Gleason Grade 6 stable prostate specific antigen ( PSA ) level Subjects plasma cell leukemia ( PCL ) Subjects deep vein thrombosis ( DVT ) Pulmonary embolism ( PE ) within 3 month prior day 1 treatment Severe infection necessitate use antibiotic / antiviral screen period Clinically relevant active infection include active hepatitis B C human immunodeficiency virus ( HBV , HCV , HIV ) concurrent disease Acute relevant abnormality electrocardiogram ( ECG ) Significant cardiac disease Pregnant breastfeed Positive serum urine pregnancy test Hypersensitivity active substance excipients study drug BT062 , history severe allergic anaphylactic reaction therapeutic protein ( e.g . reaction vaccination biological therapy )</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>August 2016</verification_date>
	<keyword>Combination</keyword>
	<keyword>Multiple Myeloma</keyword>
</DOC>